Immunohistochemical phenotype of breast carcinomas predicts the eff ectiveness of primary systemic therapy;Az emlo″daganatok primer szisztémás kemoterápiára adott válasza az immunhisztokémiai fenotípus tükrében

Magyar Onkologia

Volumn 53, Issue 4, 2009, Pages 335-343

  Kulka, Janina ^a   Tokés, Anna Mária ^a   Tóth, Adrienn Ildikó ^a   Szász, Attila Marcell ^a   Farkas, Andrea ^b   Borka, Katalin ^a   Járay, Balázs ^a   Székely, Eszter ^a   Istók, Roland ^a   Lotz, Gábor ^a   Madaras, Lilla ^a   Korompay, Anna ^a   Harsányi, László ^c   László, Zsolt ^e   Rusz, Zoltán ^f   Molnár, Béla Ákos ^c   Molnár, István Arthur ^c   Kenessey, István ^a   Szentmártoni, Gyöngyvér ^d   Székely, Borbála ^a,d   Dank, Magdolna ^d   more..

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Szent Imre Kórház ^*  (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d Radiologiai es Onkoterapias Klinika   (Hungary)

^e MaMMa Klinika Budapest   (Hungary)

^f Schöpf Merei Kórház Sebészeti Osztály   (Hungary)

Author keywords

Breast cancer; Neoadjuvant therapy; Phenotype; Primary systemic therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TAXANE DERIVATIVE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; HER2 PROTEIN, HUMAN; TAXOID; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ASPIRATION BIOPSY; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; REVIEW; ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; CHEMISTRY; METHODOLOGY; PATHOLOGY; PHENOTYPE; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOADJUVANT THERAPY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 75949125772     PISSN: 00250244     EISSN: None     Source Type: Journal    
DOI: 10.1556/MOnkol.53.2009.4.2     Document Type: Review

References (40)

1. Baselga J, Semiglazov V, Manikhas GM, et al. Efficacy of neoadjuvant trastuzumab in patients with infl ammatory breast cancer: data from the NOAH (Neoadjuvant Herceptin) phase III trial. Eur J Cancer 5:193 [abstract 2030], 2007
2. Bear HD, Anderson S, Brown A, et al. The Effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003
3. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027, 2006
4. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive oper able breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233, 2007
5. Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72:99-107, 2008
6. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007
7. Carey LA, Metzger R, Dees EC, et al. American Joint Committ ee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97:1137-1142, 2005
8. Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16:223-228, 1993
9. Dank M, Zergenyi E, Domotori ZS, et al. Primary systemic therapy (PST) of locally advanced breast cancer using Doxorubicin/ Docetaxel combination. Anticancer Res 23:2879-2880, 2003
10. Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578-2581, 1986
11. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
12. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant trastuzumab in patients with her2-positive locally advanced breast cancer: primary efficacy analysis of the noah trial. Presented at the 31st Annual San Antonio Breast Cancer Sym posium, 2008 www.abstracts2view.com/sabcs/view. php?nu=SABCS08L- 1443&terms
13. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814-819, 2008
14. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044, 2006
15. Hammock L, Lewis M, Phillips C, et al. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene Amplification by fluorescence in situ hybridization. Hum Pathol 34:1043-1047, 2003
16. Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 35:292-298, 1977
17. Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23:9304-9311, 2005
18. Heys SD, Sarkar T, Hutcheon AW. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat 90:169-185, 2005
19. Kahán Zs, Nikolényi A, Uhercsák G, Thurzó L. Neoadjuváns szisztémás terápia emlrákban. Orvosi Hetilap 150:65-71, 2009
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600-2608, 2003
22. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
23. Mamounas EP. Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin Oncol 25:31-35,1998
24. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 97:188-194, 2005
25. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12:320-327, 2003
26. Peintinger F, Buzdar AU, Kuerer HM, et al. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 19:2020-2025, 2008
27. Penault-Llorca F, Abrial C, Raoelfils I, et al. Comparison of the prognostic significance of Chevallier and Sataloff 's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol 39:1221-1228, 2008
28. Pinder SE, Provenzano E, Earl H, et al. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology 50:409-417, 2007
29. Pusztai L. Preoperative systemic chemotherapy and pathologic assessment of response. Pathol Oncol Res 14:169-171, 2008
30. Reis-Filho JS, Tutt AN. Triple negative tumours: A critical review. Histopathology 52:108-118, 2008
31. Ring AE, Ellis PA. Predictors of response to systemic therapy in breast cancer. Forum (Genova) 12:19-32, 2002
32. Ring AE, Smith IE, Ashley S, et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiv ing neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91:2012-2017, 2004
33. Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E, et al. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 10:646-653, 2008
34. Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 180:297-306, 1995
35. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat, 2009
36. Straver ME, van Adrichem JC, Rutgers EJ, et al. Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy. Ned Tdschr Geneeskd 152:2519-2525, 2008
37. Tokes AM, Szasz AM, Farkas A, et al. Stromal matrix protein expression following preoperative systemic therapy in breast cancer. Clin Cancer Res 15:731-739, 2009
38. Wang S, Yang H, Tong F, et al. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. Gan To Kagaku Ryoho 36:255-258, 2009
39. Wolff AC, Davidson NE. Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. Oncologist 7:239-245, 2002
40. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007